Allergy Therapeutics plc (AGY.L) issued a trading update for the year ended 30 June 2024. Revenue for the year ended 30 June 2024 is expected to be 7% lower at 55.2 million pounds from 59.6 million pounds, last year. Revenue for second half is expected to have increased by 2% to 21.6 million pounds from 21.2 million pounds, prior year.
The Group stated that financial turnaround is progressing with expected revenue growth in the second half, marking the first period of half year growth since 2021. The unaudited cash balance at 30 June 2024 was 12.9 million pounds.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback: editorial@rttnews.com